Harvard Apparatus (HART) Reports Q4 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bioengineered Organ Implant Developer HART Reviews Progress and Q4 2015 Results
March 17, 2016 4:21 PM EDTHOLLISTON, Mass., March 17, 2016 /PRNewswire/ --Â Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), announced its financial results for the fourth quarter and year ended December 31, 2015 and reviewed its corporate and research progress and plans.
HART is a biotechnology company developing bioengineered organ implants based on the Company's new Cellframe technology. HART's new Cellframe implant technology is comprised of a biocompatible... More
